1. Scrip
  2. >>Leadership

Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO

Jeff Jonas Remains As Chief Innovation Officer, Board Member

 
• By Mandy Jackson

When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.

Barry Greene
Barry Greene's first day as Sage CEO was 15 December • Source: Sage Therapeutics Inc.

Barry Greene was interested in pursuing opportunities related to central nervous system diseases when the long-time Alnylam Pharmaceuticals Inc. president made the decision to move on. Already familiar with Sage Therapeutics, Inc. and unable to take a long vacation between executive gigs due to the COVID-19 pandemic, Greene told Scrip, the opportunity to lead CNS drug developer Sage as its new CEO was a “no-brainer” – pun intended.

Greene’s new role was revealed on 16 December, but Sage’s prior CEO Jeff Jonas isn’t going anywhere. Jonas will remain in the newly created role of chief innovation officer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.